PMID- 34489952 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20211214 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome. PG - 702425 LID - 10.3389/fimmu.2021.702425 [doi] LID - 702425 AB - Antiphospholipid syndrome (APS) is a multisystem disorder characterized by thrombosis and/or recurrent fetal loss. This clinical phenotype heterogeneity may result in differences in response to treatment and prognosis. In this study, we aimed to identify primary thrombotic APS (TAPS) from primary obstetric APS (OAPS) using urine proteomics as a non-invasive method. Only patients with primary APS were enrolled in this study from 2016 to 2018 at a single clinical center in Shanghai. Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially expressed proteins. Cluster analysis of urine proteomics identified differentiated proteins among the TAPS, OAPS, and HC groups. Urinary proteins were enriched in cytokine and cytokine receptor pathways. Representative secreted cytokines screened out (fold change >1.20, or <0.83, p<0.05) in these differentiated proteins were measured by enzyme-linked immunosorbent assay in a validation cohort. The results showed that the levels of C-X-C motif chemokine ligand 12 (CXCL12) were higher in the urine of patients with TAPS than in those with OAPS (p=0.035), while the levels of platelet-derived growth factor subunit B (PDGFB) were lower in patients with TAPS than in those with OAPS (p=0.041). In addition, correlation analysis showed that CXCL12 levels were positively correlated with immunoglobulin G anti-beta2-glycoprotein I antibody (r=0.617, p=0.016). Our results demonstrated that urinary CXCL12 and PDGFB might serve as potential non-invasive markers to differentiate primary TAPS from primary OAPS. CI - Copyright (c) 2021 Zhou, You, Wang, Sun, Teng, Liu, Cheng, Su, Shi, Hu, Chi, Jia, Wan, Liu, Wang, Shi, Yang and Ye. FAU - Zhou, Zhuochao AU - Zhou Z AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - You, Yijun AU - You Y AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Fan AU - Wang F AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Sun, Yue AU - Sun Y AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Teng, Jialin AU - Teng J AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Liu, Honglei AU - Liu H AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Cheng, Xiaobing AU - Cheng X AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Su, Yutong AU - Su Y AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Shi, Hui AU - Shi H AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Hu, Qiongyi AU - Hu Q AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Chi, Huihui AU - Chi H AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Jia, Jinchao AU - Jia J AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wan, Liyan AU - Wan L AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Liu, Tingting AU - Liu T AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Mengyan AU - Wang M AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Shi, Ce AU - Shi C AD - Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yang, Chengde AU - Yang C AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ye, Junna AU - Ye J AD - Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210819 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Biomarkers) SB - IM MH - Adult MH - Antiphospholipid Syndrome/complications/*diagnosis/*urine MH - Biomarkers/*urine MH - Female MH - Humans MH - Middle Aged MH - Pregnancy MH - Pregnancy Complications/*diagnosis/*urine MH - Proteomics MH - Urinalysis PMC - PMC8416615 OTO - NOTNLM OT - CXCL12 OT - PDGFB OT - obstetric antiphospholipid syndrome OT - thrombotic antiphospholipid syndrome OT - urine proteomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/08 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/01/01 CRDT- 2021/09/07 07:43 PHST- 2021/04/29 00:00 [received] PHST- 2021/08/03 00:00 [accepted] PHST- 2021/09/07 07:43 [entrez] PHST- 2021/09/08 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2021.702425 [doi] PST - epublish SO - Front Immunol. 2021 Aug 19;12:702425. doi: 10.3389/fimmu.2021.702425. eCollection 2021.